ARRY Related Analyst Ratings
-
UBS Upgrades Array BioPharma (ARRY) to Buy
-
UBS Downgrades Array Biopharma (ARRY) to Neutral
-
Leerink Swann Downgrades Array Biopharma (ARRY) to Market Perform; Phase II trial of ARRY-162 Results Poor
-
Baird Downgrades Array BioPharma (ARRY) to Neutral
-
Boenning & Scattergood Initiates Coverage on Array BioPharma (ARRY)
-
Barclays Gets Bullish On US Biotechnology Sector (BBH)
-
Susquehanna Initiates Coverage on Array BioPharma (ARRY) with a Positive
-
Baird Reiterates Outperform on Array BioPharma (ARRY)
-
William Blair Starts Array BioPharma (ARRY) at Outperform
-
Morgan Joseph Starts Array BioPharma (ARRY) at Buy
-
Lehman Brothers Starts Array Biopharma (ARRY) at Overweight
-
Rodman & Renshaw Starts Array Biopharma (ARRY) at Market Outperform
-
JP Morgan Starts Array Biopharma (ARRY) at Overweight
-
ThinkEquity Starts Array Biopharma (ARRY) at Buy
-
Piper Jaffray names Array BioPharma (ARRY) a new Top Pick for 2007
-
Oppenheimer Starts Array BioPharma (ARRY) at Buy
-
WR Hambrecht Raises Price Target on Array Biopharma (ARRY) to $17
-
Banc of America Starts Array BioPharma (ARRY) at Buy
-
Robert W Baird Starts Array Biopharma (ARRY) at Outperform
-
Piper Jaffray Raises Price Target on Array BioPharma (ARRY)
-
CE Unterberg Towbin Issues Q3 Top Picks
-
Jefferies & Co Initiates Coverage on Array BioPharma (ARRY) with a Buy
-
CE Unterberg Starts Array Biopharma (ARRY) at Buy
-
WR Hambrecht comments on Array Biopharma (ARRY)
-
Merriman Curhan Starts ARRY at Buy
-
WR Hambrecht Starts ARRY at Buy
-
ARRY started at Buy at UBS; $12 price tgt
Back to ARRY Stock Lookup
